Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
The company had incurred a loss of 1 cent per share in the year-ago quarter. The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda. Revenues in the third quarter totaled $141.5 million, up 37% year over year on a reported basis and 36% on constant-currency (cc) basis. The figure beat the Zacks Consensus Estimate of $134 million. The top line comprised sales of Galafold, which is approved for Fabry disease and Pombiliti + Opfolda. The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Despite the better-than-expected results, shares of Amicus were down 4.3% on Nov. 6 following the announcement of the news. The stock has plunged 20.8% so far this year compared with the industry's decline of 2.5%. Imag
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Cantor Fitzgerald from $20.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
FOLD
Earnings
- 11/6/24 - Beat
FOLD
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 4
- 11/6/24 - Form 144
- FOLD's page on the SEC website